Eosinophilic Fasciitis Occurring under Treatment with Natalizumab for Multiple Sclerosis

Abstract

Background: Eosinophilic fasciitis is a rare sclerosing syndrome with a poorly understood etiology. Objective: We report a case of eosinophilic fasciitis in a 40-year-old man undergoing treatment with natalizumab for multiple sclerosis. Natalizumab is a selective adhesion molecule inhibitor that prevents interaction of leukocytes with endothelial cells. Peripheral blood eosinophilia has been described under treatment with natalizumab, but we herein report the first case to our knowledge of eosinophilic fasciitis as a possible complication of this medication.